divarasib
Selected indexed studies
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. (N Engl J Med, 2023) [PMID:37611121]
- Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. (Nat Med, 2024) [PMID:38052910]
- Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. (Target Oncol, 2024) [PMID:38739329]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. (2023) pubmed
- Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. (2024) pubmed
- Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. (2024) pubmed
- Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. (2025) pubmed
- The structure of KRAS(G12C) bound to divarasib highlights features of potent switch-II pocket engagement. (2024) pubmed
- Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. (2024) pubmed
- Recent advances in therapeutic targeting of the KRAS pathway in cancer. (2025) pubmed
- Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors. (2025) pubmed
- Early promising results with the novel KRAS(G12C) inhibitor divarasib. (2023) pubmed
- RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy. (2025) pubmed